Editas Medicine, Inc. EDIT incurred a loss of 55 cents per share in the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 64 cents per share. The company had reported a ...
Editas Medicine (NASDAQ:EDIT) stock rose ~6% on Wednesday after Q4 revenue beat estimates. Q4 net loss widened to -$60.74M, compared to -$41.44M in the year ago period. Collaboration and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results